[Asia Economy Reporter Kim Hyunjung] Chinese health authorities have approved their first domestically developed COVID-19 treatment.
According to local media on the 26th, the National Medical Products Administration granted conditional emergency use authorization the day before for the COVID-19 treatment "Azvudine," developed by Henan Jinshi Biotechnology and Zhengzhou University.
Bloomberg reported that this treatment will compete with Pfizer's Paxlovid, which was approved in China last February. It explained, "With this approval, China has strengthened its existing vaccine arsenal to fight the virus, helping the transition beyond zero-COVID to normal daily life."
The health authorities introduced Azvudine as the first domestically developed oral COVID-19 treatment in China. They also explained that this treatment was originally approved for market release in July last year for the treatment of human immunodeficiency virus (HIV).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
